{
  "compound": "Nabilone",
  "condition": "TOURETTE_SYNDROME",
  "effect_size": "Medium-large (d = 0.71)",
  "study_type": "RCT",
  "source": "NORML:TS_RCT_006",
  "participants": "16 adults with TS",
  "year": 2019,
  "notes": "Nabilone for Tourette Syndrome: Pilot Randomized Trial",
  "confidence": "medium",
  "abstract": "Nabilone: 35% tic reduction vs Placebo: 12% (p<0.05); Proof of concept for FDA-approved cannabinoid"
}